Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised application seeking full approval of the shot for adults ages 50 to 64, and ...

Although the Centers for Disease Control and Prevention (CDC) classifies the current flu season as “moderate,” at least 90 children have already died of influenza. Among the children who died and were ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.

The US FDA’s vaccine advisors have recommended that three new influenza strains be included in next winter’s influenza vaccine, aiming in part to tamp down illness caused by subclade K, a mutated form ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine. The agency’s decision, which Moderna announced in a press ...

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found ...

The U.S. Food and Drug Administration (FDA) refused to consider Moderna’s application for a new flu vaccine using mRNA technology, the company announced Tuesday, a decision that could delay the ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...

The FDA has agreed to review Moderna’s investigational flu vaccine for potential approval, about a week after telling the drugmaker it would not consider the application. On Feb. 10, the agency ...